Details for Patent: 8,388,941

Which drugs does patent 8,388,941 protect, and when does it expire?

Patent 8,388,941 protects TRAVATAN Z and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 8,388,941

Title:	Self preserved aqueous pharmaceutical compositions
Abstract:	The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being `self-preserved`. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.
Inventor(s):	Chowhan; Masood A. (Arlington, TX), Keith; David J. (Washington, MO)
Assignee:	Alcon Research, Ltd. (Fort Worth, TX)
Application Number:	12/441,995
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,388,941
Patent Claim Types: see list of patent claims	Composition; Use;

Drugs Protected by US Patent 8,388,941

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT	RX	Yes	Yes			Y

Foreign Priority and PCT Information for Patent: 8,388,941

PCT Information
PCT Filed	September 20, 2007	PCT Application Number:	PCT/US2007/079094
PCT Publication Date:	April 10, 2008	PCT Publication Number:	WO2008/042619

International Family Members for US Patent 8,388,941

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007304996
Brazil	PI0717093
Canada	2663817
China	101522171
European Patent Office	2066300
Spain	2543349
Hong Kong	1126419